Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: Results from the UroScreen-Study

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1656-1662

  Banek, Severine ^a   Schwentner, Christian ^a   Täger, Dirk ^b   Pesch, Beate ^b   Nasterlack, Michael ^c   Leng, Gabriele ^d   Gawrych, Katarzyna ^b   Bonberg, Nadine ^b   Johnen, Georg ^b   Kluckert, Mattias ^b,e   Gakis, Georgios ^a   Todenhöfer, Tilman ^a   Hennenlotter, Joerg ^a   Brüning, Thomas ^b   Stenzl, Arnulf ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c BASF SE   (Germany)

^d Bayer Industry Services GmbH and Co OHG   (Germany)

^e INSTITUT FÜR ARBEITSSCHUTZ DER DEUTSCHEN GESETZLICHEN UNFALLVERSICHERUNG IFA   (Germany)

Author keywords

Bladder cancer; Confounder; Early detection; FISH; Hematuria; Renal function

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CONTROLLED STUDY; CREATININE URINE LEVEL; CYSTOSCOPY; CYTOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATURIA; HISTOPATHOLOGY; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; URINALYSIS;

BLADDER CANCER; CONFOUNDER; EARLY DETECTION; FISH; HEMATURIA; RENAL FUNCTION;

ADULT; AGED; AGED, 80 AND OVER; CREATININE; CYSTOSCOPY; EARLY DETECTION OF CANCER; GENETIC TESTING; HEMATURIA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; ROC CURVE; URINARY BLADDER NEOPLASMS;

EID: 84886234167     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.04.015     Document Type: Article

References (32)

1. Hentschel S., Pritzkuleit R., Schmid-Höpfner S., et al. Epidemiologische Krebsregistrierung in Deutschland. Onkologie 2011, 17:97-106.
2. Golka K., Wiese A., Assennato G., et al. Occupational Exposure and Urological Cancer. World J Urol 2004, 21:382-391.
3. Golka P., Goebbel A. Rettenmeier: Ätiologie und Prävention des Harnblasenkarzinoms, Deutsches 2007, 719-723. Heft, Ärzteblatt: JG, 11.
4. Pesch B., Haerting J., Ranft U., et al. Occupational risk factors for urothelial carcinoma: Agent-specific results from a case-control study in Germany. MURC Study Group. Mulitcenter urothelial and renal cancer study. Int J Epidemiol 2000, 2:238-247.
5. Mowatt G., Zhu S., Kilonzo M., et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010, 14:4.
6. Nasterlack M., Feil G., Leng G., et al. [Bladder cancer screening with urine-based tumor markers-occupational medical experience]. Aktuelle Urol 2011, 42(2):128-134.
7. Pesch B., Nasterlack M., Eberle F., et al. The role of hematuria in BC screening among men with former occupational exposure to aromatic amines. BJU Int 2011, 108:546-552.
8. Papanikolaou G.N., Marshall V.F. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 1945, 101:519-520.
9. Rathert P., Roth S. Urinzytologie. Praxis und Atlas 1991, Springer, Berlin.
10. Produktinformation® Vysis: FISH Bladder Cancer Recurrence Kit 2010, Vysis, Vysis Inc., Abbott Park, IL.
11. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49. 466-5.
12. Hong Y.M., Loughlin K.R. Loughlin KR: Economic impact of tumor markers in bladder cancer surveillance. Urology 2008, 71:131-135.
13. Botteman M.F., Pashos C.L., Redaelli A., et al. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 2003, 21:1315-1330.
14. Bruyninckx R., Buntinx F., Aertgeerts B., et al. The diagnostic value of macroscopic hematuria for the diagnosis of urological cancer in general practice. Br J Gen Pract 2003, 53:31-35.
15. Cohen R.A., Brown R.S. Clinical practice. Microscopic hematuria. N Engl J Med 2003, 348:2330-2338.
16. Babjuk M., Oosterlinck W., Sylvester R., et al. European association of urology (EAU): EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Review. Eur Urol 2008, 54:303-314.
17. Schwarz S., Rechenmacher M., Filbeck T., et al. Value of multicolor fluorescence in situ hybridization (FISH) in the differential diagnosis of flat urothelial lesions. J Clin Pathol 2008, 61:272-277.
18. Volpe A., Racioppi M., D'Agostino D., et al. Bladder tumor markers: A review of the literature. Int J Biol Markers 2008, 23:249-261.
19. Halling K.C., King W., Sokolova I.A., et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis FISH assays for the detection of urothelial carcinoma in urine. J Urol 2002, 167:2001-2006.
20. Sarosdy M.F., Schellhammer P., Bokinsky G., et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002, 168:1950-1954.
21. Rodgers M., Nixon J., Hempel S., et al. Diagnostic tests and algorithms used in the investigation of hematuria: Systematic reviews and economic evaluation. Health Technol Assess 2006, 10:iii-iv. xi-259.
22. Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: International consensus Panel on bladder tumor markers. Urology 2005, 66(Suppl 1):35-63.
23. Wojcik E.M., Brownlie R.J., Bassler T.J., et al. Superficial urothelial (umbrella) cells. A potential cause of abnormal DNA ploidy results in urine specimens. Anal Quant Cytol Histol 2000, 22:411-415.
24. Bubendorf L., Dalquen P., Savic S. Cytology of the urinary tract. Between uncertainly and clarity. Pathologe 2009, 30:173-178.
25. K Lindemann-Docter N.T., Gaisa D., Smeets R. Knüchel-Clarke: Uringebundene Marker mit besonderer Berücksichtigung der Fluoreszenz-in-situ-Hybridisierung. (FISH). Urologe 2011, 50:297-302.
26. Sadetzki S., Bensal D., Blumstein T., et al. Selected risk factors for transitional cell bladder cancer. Med Oncol 2000, 17:179-182.
27. Bobiński J., Lipiński M. [EORTC risk tables-a new diagnostic tool in urology]. Review. Pol Merkur Lek 2009, 27:524-528. [Polish].
28. Hernández V., De La Peña E., Martin M.D., et al. External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. World J Urol 2010, 29:409-414.
29. Herr H.W., Donat S.M. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumor recurrences. BJU Int 2008, 102:1111-1114.
30. Zaak D., Hungerhuber E., Schneede P., et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 2002, 95:1234-1238.
31. Stenzl A., Jocham D., Jichlinska P., et al. Photodynamische Diagnostik im Harntrakt. Konsensusempfehlungen des Arbeitskreises Onkologie der Deutschen Gesellschaft für Urologie. Urologe A 2008, 47:982-987.
32. Riley G.F., Potosky A.L., Lubitz J.D., et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995, 33:828-841.